| Pharmaceutical Information |
| Drug Name |
Fosamprenavir calcium |
| Drug ID |
BADD_D00961 |
| Description |
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. |
| Indications and Usage |
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults. |
| Marketing Status |
approved |
| ATC Code |
J05AE07 |
| DrugBank ID |
DB01319
|
| KEGG ID |
D03835
|
| MeSH ID |
C426859
|
| PubChem ID |
131535
|
| TTD Drug ID |
D0F5MT
|
| NDC Product Code |
49702-208; 65015-806; 49702-207; 63379-087; 63304-583; 0378-3520 |
| UNII |
ID1GU2627N
|
| Synonyms |
fosamprenavir | fos-amprenavir | (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester | VX-175 | VX 175 | GW-433908 | GW 908 | GW433908 | GW 433908 | GW-908 | fosamprenavir sodium | GW 433908A | GW-433908A | fosamprenavir calcium | Telzir | GW 433908G | GW-433908G | GW433908G | Lexiva |
|
| Chemical Information |
| Molecular Formula |
C25H34CaN3O9PS |
| CAS Registry Number |
226700-81-8 |
| SMILES |
CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3=CC=C(C=C3)
N.[Ca+2] |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Hyperlipidaemia | 14.08.03.001 | - | - | | | Lipohypertrophy | 14.08.04.009; 23.07.01.005 | - | - | | | Graves' disease | 05.02.02.009; 06.09.04.009; 10.04.08.014 | - | - | - |
|
|
|
